The present invention relates to solid oral pharmaceutical compositions comprising ticagrelor or salts thereof. In particular, the present invention relates to a composition comprising ticagrelor or salts thereof in an amount less than 20 % of the weight of total composition and at least one pharmaceutically acceptable excipient. The invention further relates to method of reducing the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) by using the composition ticagrelor or salts thereof.
